Acute Ischemic Stroke (AIS) Market Size to Exceed USD 13.11 Bn by 2032

The Acute Ischemic Stroke (AIS) Market, estimated at USD 9.96 Bn in 2025, is expected to exhibit a CAGR of 4% and reach USD 13.11 Bn by 2032.

The market growth is driven by increasing demand for innovative and effective drugs across diverse therapeutic areas. Advances in drug discovery, biopharmaceuticals, and digital technologies are improving treatment outcomes and operational efficiency. Supportive regulations, rising R&D investments, and a strong focus on patient-centric care are creating new opportunities for pharmaceutical companies.

Key market players are focusing on adoption of growth strategies such as launch of new productsand this is expected to drive the global acute ischemic stroke (AIS) market growth. For instance, in November 2020, AstraZeneca, a science-led biopharmaceutical company, announced the launch of the product Brilinta (an oral, reversible, direct-acting P2Y12 receptor antagonist) that  is used to reduce the risk of stroke, a leading global cause of disability and death in patients with acute ischemic stroke or high-risk transient ischemic attack (TIA).

Global Acute Ischemic Stroke (AIS) Market– Impact of Coronavirus (COVID-19) Pandemic

The World Health Organization (WHO) designated the illness caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), which first appeared in Wuhan (province of Hubei, China), in the last months of 2019, as "coronavirus disease 2019" or COVID-19. This virus spreads quickly, and had a serious negative impact on the economies, social behaviors, and healthcare of every country in the world.

COVID-19 affected the economy in three main ways: by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to the lockdown, several countries such as India, China, Brazil, and others faced problems regarding transportation of things from one place to another.

However, the COVID-19 pandemic had positive impact on the global acute ischemic stroke (AIS) market, owing to use of tissue plasminogen activator (tPA) in treating COVID-19. For instance, in March 2020, according to a new study published in the Journal of Trauma and Acute Care Surgery, , the anticoagulation drug tPA could be a potential aid in managing respiratory failure in COVID-19 patients, alleviating the expected shortage of ventilators for patients with severe COVID-19 infections.

Global Acute Ischemic Stroke (AIS) Market: Key Developments

On January 23, 2023, Julier Medical, a France-based medical device company that engages in developing an innovative solution for the removal of blood clots and post-stroke revascularization, announced a successful US$ 3 Mn seed financing from Sofinnova Partners, a leading life sciences venture capital firm in Europe. The funds will support the development of Julier Medical’s mechanical thrombectomy device to treat patients with Acute Ischemic Stroke (AIS).

In June 2022, ACTICOR BIOTECH, a clinical-stage biotechnology company that specializes  in the development of innovative drugs for the treatment of cardiovascular emergencies, particular for stroke, announced that the European Patent Office (EPO) had  granted a new patent that strengthens Acticor Biotech's patent portfolio. It provides protection for the use of glenzocimab in thrombotic diseases in Europe until 2036.

In November 2021, ACTICOR BIOTECH, a clinical stage biotechnology company, announced that the U.S Food and Drug Administration (FDA)  had  approved the  initiation of a clinical trial in U.S. with glenzocimab, a novel humanized monoclonal antibody fragment, for use in patients with acute ischemic stroke.

In May 2021, DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical companythat focuses on developing novel treatments for treatment of neurological disorders and kidney diseases, announced that the U.S. Food & Drug Administration (FDA) had accepted the company’s Investigational New Drug (IND) application. The company plans to proceed with a pivotal Phase 2/3 study of DM199 (recombinant human tissue kallikrein-1or KLK1) for the treatment of patients with Acute Ischemic Stroke (AIS).

Browse 26 Market Data Tables and 28 Figures spread through 180 Pages and in-depth TOC on “Global Acute Ischemic Stroke (AIS) Market”- Forecast to 2030, Global Acute Ischemic Stroke (AIS) Market, By Therapeutics (Tissue Plasminogen Activator, Anticoagulant, Antiplatelet, and Antihypertensive), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/acute-ischemic-stroke-therapeutics-market-4483

Key Takeaways of the Global Acute Ischemic Stroke (AIS) Market:

• Global acute ischemic stroke (AIS) market is expected to exhibit a CAGR of 4% during the forecast period, owing to increasing research and development activities by key market players to expand their product portfolio. For instance, in August 2021, Lumosa Therapeutics, a clinical stage biotechnology company, announced that its Phase 2a clinical trial of LT3001 had successfully met its primary safety endpoint. Further, efficacy showed potential for improvements in neurological and functional outcomes based on the majority of LT3001 patients with baseline National Institutes of Health stroke scale (NIHSS) ≥6 demonstrating pronounced neurological improvement (NIHSS improvement ≥4 points). This study was conducted in the U.S. and Taiwan, and was designed to evaluate LT3001 versus placebo/control in subjects with Acute Ischemic Stroke (AIS) within 24 hours after stroke symptoms onset.
• Among therapeutics, the tissue plasminogen activator segment is expected to hold a dominant position in the global acute ischemic stroke (AIS) market during the forecast period due to increasing organic growth strategies such as product launch by key market players to expand their product portfolio. For instance, in February 2020, Reliance Life Sciences Private Limited, a research-driven organization, launched three biosimilars such as interferon beta, reteplase, and human chorionic gonadotropin. Reteplase is a purified version of human tissue plasminogen activator that is used to treat myocardial infarction, ischemic stroke, and pulmonary embolism in the event of an emergency.
• Among region, North America is expected to be the dominant region in the global acute ischemic stroke (AIS) market, owing to increasing research and development activities by key market players to expand their product. For instance, in September 2021, DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company that focuses on developing novel treatments for neurological disorders and kidney diseases, announced the initiation of the first site for its pivotal ReMEDy2 Trial, a Phase 2/3 clinical study of DM199 for the treatment of acute ischemic stroke (AIS).
• Major players operating in the global acute ischemic stroke (AIS) market are F. Hoffmann-La Roche Ltd, Boehringer Ingelheim International GmbH, Bayer AG, Pfizer Inc., Biogen, DAIICHI SANKYO COMPANY, LIMITED, Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc., AstraZeneca, SanBio Co,Ltd., Athersys, Inc., Abbott, Sanofi, ZZ Biotech, Teva Pharmaceutical Industries Ltd, Merck & Co., Inc., NoNO Inc., AliveCor, Inc., Amgen Inc., Genentech USA, Inc., DiaMedica Therapeutics, Inc.